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106One pitfall of reporting response is the phenomenon of “regres-
sion to the mean.” If enrollment requires a measurement below a
certain threshold, using a test with an element of variability, such as
LVEF, a measurement taken on 1 particular day might be lower
than the patients’ true average value. When the test is repeated (after
the intervention), the measurement is likely to have risen closer to
the patients’ true average. This may give the false impression of a
therapeutic improvement. Unless there is a control group for com-
parison, a reader may be misled into thinking that an intervention is
effective. Describing an intervention as “effective” should be reserved
for the ﬁndings of randomized controlled trials where there is a
signiﬁcant difference between the intervention and control groups.
The terms “outcome,” “response,” and “effect” are sometimes used
interchangeably in imaging research. We suggest simple deﬁnitions
to facilitate clear communication and avoid misinterpretation of
ﬁndings and even of study design.
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Qualitative Characterization of
Adipose Tissue by MDCT
We read with great interest the paper by Rosenquist et al. (1)
published recently in iJACC. The analysis performed on a large
cohort drawn from the Framingham Heart Study implies that lower
multidetector computed tomography (MDCT) attenuation of sub-
cutaneous adipose tissue and visceral adipose tissue is associated
with an adverse cardiometabolic risk proﬁle. We would like to reﬂect
on 2 aspects of the published data.
First, although imaging of adipose tissue by MDCT offers
relatively high resolution and reproducibility and has increasingly
been used as a research tool, the methodology of computed to-
mography fat volume calculations has never been validated. Mea-
surements are based on an arbitrary attenuation range (Hounsﬁeld
units), which is not set uniformly across the literature. Such
attenuation-based identiﬁcation may lead to the parts of adipose
tissue with the lowest and highest attenuation being left unac-
counted for. Furthermore, attenuation relies substantially on
computed tomography scan parameters, especially tube voltage (kV),
and also on patients’ characteristics. Tube voltage is often set
differently for lean and obese patients. All of these factors may lead
to a systematic bias in interpretation of a study such as that by
Rosenquist et al. (1). Scan parameters applied in the reported cohort
were not mentioned in the paper.Second, we know from basic research studies that adipose tissue may
display either an unfavorable or a favorable metabolic proﬁle (endocrine
and paracrine) depending on its location and metabolic status (2). As
an example, epicardial adipose tissue in patients with coronary artery
disease as opposed to patients without this disease showed intense
leukocyte inﬁltration, thickened interlobular septa, and increased neo-
vascularization (3). All of these elements are more radiodense than
lipid-laden adipocytes and thus may lead to higher, rather than lower,
MDCT attenuation of adipose tissue with a proinﬂammatory and
proatherosclerotic metabolic proﬁle. Results of our clinical study
corroborate this hypothesis (4). Furthermore, as noted by Rosenquist et
al. (1), lower attenuation of subcutaneous adipose tissue and visceral
adipose tissue was correlated with fat volume because larger, lipid-laden
adipocytes are less attenuating. In such circumstances, in a retrospec-
tive, cross-sectional study, it may be difﬁcult to distinguish the effects of
fat volume from those of its attenuation. Thus, it would be interesting
to see how the attenuation correlated with cardiometabolic risk factors
within subgroups with similar fat volumes.
To summarize, the study by Rosenquist et al. (1) adds signiﬁ-
cantly to the growing body of evidence on the research and clinical
role of MDCT-derived characterization of adipose tissue. However,
further research efforts to eliminate the aforementioned limitations
are warranted. Longitudinal designs, histopathology references,
methodological improvements, standardization of MDCT fat
measurements, and prospective methods of accounting for the
established confounding factors in adipose tissue attenuation and
volume measurements should be clariﬁed to further develop this
new, fascinating area of research.
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Myocardial Extracellular Volume
Measurement by Cardiac Magnetic
Resonance
Measuring myocardial extracellular volume (ECV) with cardiovascular
magnetic resonance is achieving increasing importance because it allows
quantiﬁcation of diffuse ﬁbrosis not detectable with conventional late
gadolinium enhancement techniques. However, the conditio sine qua
